James Corbett, Sonic AI

Skip to content

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

James Corbett, Sonic AI

Home/Library/James Corbett

J

James Corbett

Transformational MedTech CEO · Person

20

Mentions

1

Episodes

20

Claims

James Corbett - Transformational MedTech CEO. Tracked across 20 mentions in podcasts and expert conversations analyzed by Sonic.

What James Corbett has said

After a Minnesota Business Journal article quoted James Corbett saying "I show up every day with a sledgehammer and I swing it until things go my way," his primary investor at Warburg Pincus ordered 100 reprints to send to their other portfolio company CEOs as an example of desired leadership.

bullish·James Corbett

Under James Corbett's leadership, EV3 experienced approximately 32 consecutive quarters of 50% or greater growth.

bullish·James Corbett

During James Corbett's tenure, Boston Scientific achieved just under 32 consecutive quarters of 50% or greater growth.

bullish·James Corbett

After a Minnesota Business Journal article quoted James Corbett saying "I show up every day with a sledgehammer and I swing it until things go my way," his primary investor at Warburg Pincus ordered 1...

Expert perspectiveJames CorbettJun 24

Under James Corbett's leadership, EV3 experienced approximately 32 consecutive quarters of 50% or greater growth.

Expert perspectiveJames CorbettJun 24

During James Corbett's tenure, Boston Scientific achieved just under 32 consecutive quarters of 50% or greater growth.

Expert perspectiveJames CorbettJun 24

James Corbett has launched a free-to-use AI tool called the "AI Command Center" available at jimcorbettai.com.

Expert perspectiveSaulJun 24

Throughout his career, James Corbett has been involved in over $1 billion in financing deals.

Expert perspectiveSaulJun 24

James Corbett has served as president or CEO in the medtech industry for over 30 years at companies including Boston Scientific, EV3, and AlphaTech.

Expert perspectiveSaulJun 24

Transcatheter valve replacement technology, initially developed for elderly patients unable to undergo surgery, has now expanded its applicability to almost all patient populations.

Expert perspectiveJames CorbettJun 24

The American Medical Association holds a congressional monopoly over the CPT code system for medical procedures.

Expert perspectiveJames CorbettJun 24

James Corbett alleges that the American Medical Association selectively enforces its own CPT process rules, following them when convenient and breaking them when not.

Expert perspectiveJames CorbettJun 24

In the early 1990s, 70% of biotech companies were led by former Baxter executives due to Baxter's effective, decentralized approach to developing CEOs.

Expert perspectiveJames CorbettJun 24

James Corbett asserts that IT departments in large corporations are attempting to halt the proliferation of AI, thereby hindering their companies' future progress.

Expert perspectiveJames CorbettJun 24

The Watchman device from Boston Scientific, which occludes the left atrial appendage to prevent strokes in AFib patients, has successfully created a major new product category in medtech.

Expert perspectiveJames CorbettJun 24

The primary obstacles to bringing new medical device categories to market are the generation of scientific evidence, followed by navigating the American Medical Association's CPT process and the CMS p...

Expert perspectiveJames CorbettJun 24

In its early years, medtech company EV3 faced a strategic crisis where its portfolio development commitments exceeded the amount of capital it could realistically raise from its primary backer, Warbur...

Expert perspectiveJames CorbettJun 24

James Corbett believes the LSI (Life Science Intelligence) conference has become the equivalent of the JPMorgan Healthcare Conference for private companies.

Expert perspectiveJames CorbettJun 24

James Corbett believes that 90% or more of companies and executives are using AI for mundane, easy tasks rather than for business transformation.

Expert perspectiveJames CorbettJun 24

The book "Career Imprints" analyzes the distinct career development strategies of Baxter, Abbott, Merck, and Johnson & Johnson.

Expert perspectiveJames CorbettJun 24

After hiring John Shelhorn, Boston Scientific's Australian subsidiary grew its revenue to $12 million in its first year and $20 million in its second year.

Expert perspectiveJames CorbettJun 24

According to James Corbett's summary of the book "Career Imprints," Johnson & Johnson's strategy was to develop functional experts who would remain in a single function like marketing or manufacturing...

Expert perspectiveJames CorbettJun 24

James Corbett states that the book "Career Imprints" characterized Merck's culture as a "scientific oligarchy" where career progression was dependent on having a PhD and making significant inventions.

Expert perspectiveJames CorbettJun 24

Create a free account to see James Corbett's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail